Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
652.00    -4.00 (-0.61%)
Bid:
650.00
Ask:
653.00
Spread: 3.00 (0.462%)
Market Cap: £530.70m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

6 Jan 2009 08:41

RNS Number : 1619L
Bloomsbury Publishing PLC
06 January 2009
 



 

Bloomsbury Publishing Plc

("Bloomsbury")

Bloomsbury acquires Arden Shakespeare

Bloomsbury Publishing Plc is pleased to announce the acquisition of Arden Shakespeare from Cengage Learning. This transaction is not material to Bloomsbury.

  Arden Shakespeare is the most academically rigorous Shakespeare series in print, and the best-known English literature brand worldwide. Originally created by the British publishing firm of Methuen in the late nineteenth century, and edited by a distinguished collection of scholars, the series took 25 years to complete from the launch of the first title, Edward Dowden's Hamlet, in 1899. In 1995 the Third Series of The Arden Shakespeare was launched. Now published under the imprint Arden Shakespeare, under the General Editorship of Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen, the Arden Shakespeare Third Series is nearing completion. Each new volume supersedes the corresponding Second Series text, being meticulously edited from the original sources by a contemporary scholar.

Arden Shakespeare will retain its internationally recognised name and become part of the Methuen Drama imprint (acquired in 2006 by A&C Black which is a wholly owned subsidiary of Bloomsbury). The acquisition will make Methuen Drama Europe's largest performing arts list, which includes work by Bertolt Brecht, Oscar Wilde, Bernard Shaw and Arthur Miller as well as contemporary playwrights such as Michael Frayn and Willy Russell, Methuen Student editions and the New Mermaids critical editions.

'I am delighted that the Arden Shakespeare series is returning to MethuenArden is a highly prestigious addition to our performing arts publishing and fits perfectly with our strategy of acquiring high quality perennial publishing lists which have significant potential for digital exploitation. We look forward to working with the Arden General Editors Richard Proudfoot, Ann Thompson, David Scott Kastan and Henry Woudhuysen to grow and strengthen this important list' says A&C Black Managing Director, Jill Coleman.

Jill Jones, CEO Cengage Learning EMEA said, 'The Arden Shakespeare is an excellent fit for Bloomsbury: we wish A&C Black, all volume editors, authors and General Editors from the Arden Shakespeare success for the future'.

www.methuendrama.com

-ends-

For further enquiries:

Bloomsbury Publishing PLC

Jill Coleman, Bloomsbury Publishing Plc care of Bell Pottinger

Bell Pottinger Corporate & Financial

Ben Woodford / Rosanne Perry +44 (0)20 7861 3232

Notes to Editors

About Bloomsbury Publishing Plc 

(www.bloomsbury.com and www.bloomsbury-ir.co.uk)

Bloomsbury Publishing is one of the world's leading independentpublicly quoted publishing houses with a reputation for a high quality management team and a highly valuable portfolio of intellectual properties including the Encarta World English Dictionary, JK Rowling's Harry Potter, Margaret Atwood, John Irving, David Guterson and Ben Schott. Other databases include Who's Who, Whitaker's AlmanackReed's Nautical Almanac, Black's Medical Dictionary, the Macmillan English Dictionary for Advanced Learners of EnglishBusiness: The Ultimate Resource and RSPB Handbook of British Birds. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUNOWRKKRARRR
Date   Source Headline
5th Oct 20109:12 amRNSHolding(s) in Company
13th Sep 201012:20 pmRNSHolding(s) in Company
26th Aug 20107:00 amRNSInterim Results
6th Aug 201012:07 pmRNSNotice of Results
24th Jun 201011:46 amRNSHolding(s) in Company
11th Jun 20104:50 pmRNSTransaction in Own Shares
2nd Jun 20107:00 amRNSInvestor Day
28th May 20105:40 pmRNSResult of AGM
28th May 20105:36 pmRNSTransaction in Own Shares
28th May 20102:48 pmRNSTransaction in Own Shares
28th May 201012:15 pmRNSDirectorate Change
20th May 20105:55 pmRNSTransaction in Own Shares
20th May 20101:07 pmRNSHolding(s) in Company
18th May 20107:00 amRNSInterim Management Statement
11th May 20105:38 pmRNSDirector/PDMR Shareholding
7th May 20104:46 pmRNSDirector/PDMR Shareholding
27th Apr 20105:03 pmRNSHolding(s) in Company
23rd Apr 20109:12 amRNSHolding(s) in Company
22nd Apr 20103:10 pmRNSHolding(s) in Company
1st Apr 20109:41 amRNSDirector/PDMR Shareholding
30th Mar 20107:00 amRNSFinal Results
23rd Mar 201010:43 amRNSAdditional Listing
9th Mar 201010:53 amRNSNotice of Results
18th Jan 20105:59 pmRNSDirector/PDMR Shareholding
18th Jan 201012:24 pmRNSHolding(s) in Company
14th Jan 20107:00 amRNSTrading Statement
27th Nov 200911:48 amRNSHolding(s) in Company
12th Nov 20099:21 amRNSHolding(s) in Company
12th Nov 20099:17 amRNSHolding(s) in Company
10th Nov 20091:41 pmRNSHolding(s) in Company
9th Nov 200912:14 pmRNSHolding(s) in Company
4th Nov 20095:35 pmRNSHolding(s) in Company
2nd Nov 20099:57 amRNSHolding(s) in Company
23rd Oct 200912:25 pmRNSHolding(s) in Company
23rd Oct 200912:09 pmRNSHolding(s) in Company
15th Oct 20097:00 amRNSInterim Management Statement
28th Sep 20093:36 pmRNSDirector/PDMR Shareholding
27th Aug 20097:00 amRNSHalf Yearly Report
25th Aug 20092:06 pmRNSHolding(s) in Company
7th Aug 20099:30 amRNSNotice of Results
22nd Jul 20095:09 pmRNSHolding(s) in Company
16th Jul 20093:02 pmRNSBlocklisting Interim Review
16th Jul 20093:02 pmRNSBlocklisting Interim Review
16th Jul 20093:01 pmRNSBlocklisting Interim Review
16th Jul 20093:00 pmRNSBlocklisting Interim Review
16th Jul 20092:58 pmRNSBlocklisting Interim Review
16th Jul 20092:58 pmRNSBlocklisting Interim Review
16th Jul 200911:54 amRNSHolding(s) in Company
16th Jul 200911:32 amRNSBlocklisting Six Monthly Return
16th Jul 200911:30 amRNSBlocklisting Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.